Clofarabine in pediatric acute leukemia: Current findings and issues

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 417-422

  Hijiya, Nobuko ^a   Barry, Elly ^b   Arceci, Robert J ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Sanofi Oncology   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

ALL; Clofarabine; New agent; Relapse

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARAGINASE MACROGOL; ASPARTATE AMINOTRANSFERASE; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYADENOSINE; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; PERFOSFAMIDE; TRIACYLGLYCEROL LIPASE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHILDHOOD LEUKEMIA; CYTOGENETICS; DEHYDRATION; DIARRHEA; DNA METHYLATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EPIGENETICS; FEBRILE NEUTROPENIA; FUNGAL SINUSITIS; GENE SILENCING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; LEUKEMIA REMISSION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG EDEMA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84861726534     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24112     Document Type: Review

References (34)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28: 2625-2634.
2. Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 2005; 103: 1985-1995.
3. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762-1769.
4. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45-51.
5. Ghanem H, Jabbour E, Faderl S, et al. Clofarabine in leukemia. Expert Rev Hematol 2010; 3: 15-22.
6. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917-1923.
7. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118: 6043-6049.
8. Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23: 2259-2264.
9. Cooper T, Alonzo TA, Gerbing RB, et al. A report from the children's oncology group on the safety of clofarabine in combination with cytarabine in pediatric patients with relapsed acute leukemia. The American Society of Hematology 53rd annual meeting 2010 (3076).
10. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009; 147: 371-378.
11. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51: 2386-2394.
12. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5: 2438-2444.
13. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-3543.
14. Waud WR, Schmid SM, Montgomery JA, et al. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000; 19: 447-460.
15. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, et al. Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem 1992; 35: 397-401.
16. Takahashi T, Kanazawa J, Akinaga S, et al. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999; 43: 233-240.
17. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1992; 89: 2970-2974.
18. Dykes D. Response of subcutaneous HT-29 colon tumor to combination treatment with oxaliplatin and clofarabine. Birmingham, AL: Southern Research Institute; 2003. Report.
19. Dykes D. Response of subcutaneous CCRF-CEM leukemia to combination treatment with Ara C and clofarabine. Birmingham, AL: Southern Research Institute 2002. Report.
20. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167-1173.
21. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-2386.
22. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389-2395.
23. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784-789.
24. Kearns PMG, Nelken B, et al. BIOV-111a European phase II trial of clofarabine (Evoltra) in refractroy and relapsed childhood acute lymphoblastic leukemia. Blood 2006; 108: abstract #1859.
25. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940-947.
26. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008; 113: 2090-2096.
27. Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580-3589.
28. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol 2008; 26: 3971-3978.
29. Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006; 5: 855-863.
30. Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010; 28: 2755-2760.
31. Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013-3022.
32. Zhang Y, Zhang J, Shahriar M, et al. Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens. ASH Annual Meeting Abstracts 2008; 112: 379.
33. Majda K, Kaufman-Szymczyk A, Lubecka-Pietruszewska K, et al. Influence of clofarabine on transcriptional activity of PTEN, APC, RARB2, ZAP70 genes in K562 cells. Anticancer Res 2010; 30: 4601-4606.
34. O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011; 154: 482-485.